Bank Julius Baer & Co
LOGC

Bank Julius Baer & Co’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Bank Julius Baer & Co’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-19,450
Closed -$13K – 635
2022
Q1 		$13K Buy
+19,450
New +$21.3K ﹤0.01% 566

Other funds holding LOGC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank Julius Baer & Co's LOGC Position: Q2 2022 in Review

Bank Julius Baer & Co sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q2 2022, closing a stake of 19,450 shares — an estimated $13K sold.

Bank Julius Baer & Co first reported a position in LOGC in Q1 2022 and held it in 1 quarter. The position peaked at $13K in Q1 2022. 47 funds tracked by Wall St. Rank hold LOGC as of Q2 2022.

  • Bank Julius Baer & Co reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Bank Julius Baer & Co sold 19,450 LogicBio Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $13K.
  • Bank Julius Baer & Co first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Bank Julius Baer & Co's LogicBio Therapeutics, Inc. Common Stock position peaked at $13K in Q1 2022.
  • 47 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Bank Julius Baer & Co's 13F filing for Q2 2022, filed 22 Jul 2022.